Hawley UNLEASHES Total Ban on Dominant Abortion Drug

Senator Josh Hawley’s new legislation to completely ban the abortion pill mifepristone represents a direct challenge to pharmaceutical industry profits and federal regulatory authority, potentially eliminating the method used in 63% of all abortions nationwide.

Story Snapshot

Senator Josh Hawley introduced the Safeguarding Women from Chemical Abortion Act on March 11, 2026, seeking to revoke FDA approval of mifepristone and ban the drug completely
The bill allows women who experience complications to sue manufacturers directly, targeting companies like Danco Laboratories that profit from the abortion pill
Mifepristone accounts for 63% of all abortions in the United States, making it the dominant abortion method since Biden-era FDA policies allowed mail-order distribution
The legislation’s future remains uncertain as President Trump previously indicated he would veto a national abortion ban, creating questions about executive support

Hawley Targets Abortion Pill Industry

Senator Josh Hawley introduced the Safeguarding Women from Chemical Abortion Act in the Senate on March 11, 2026, legislation designed to revoke the FDA’s approval of mifepristone and ban the drug entirely. Congresswoman Diana Harshbarger introduced companion legislation in the House. The Missouri Republican held a Capitol press conference featuring testimonies from women who reported complications from the abortion pill, alongside pro-life leaders who argued the drug poses significant health risks. Hawley framed the issue as protecting women from a dangerous pharmaceutical product that generates billions in profits for manufacturers.

The bill includes provisions allowing women to sue mifepristone manufacturers for damages, creating new legal liability for pharmaceutical companies involved in medication abortion. Hawley stated that major companies like Danco Laboratories profit substantially from the drug while ignoring safety concerns. This represents the senator’s second legislative attempt to restrict mifepristone access, following a May 2025 bill that sought FDA safeguards rather than complete prohibition. The current legislation takes a more aggressive approach by attempting to withdraw approval granted during the Clinton administration in 2000.

Biden Administration’s Mail-Order Abortion Legacy

The Biden administration implemented FDA policies allowing mail-order distribution of abortion pills, fundamentally transforming abortion access in America. Pro-life organizations estimate these policies drive approximately 500 abortions per day through mail-order prescriptions. Mifepristone became the dominant abortion method in the United States, accounting for 63% of all abortions in 2023 according to Guttmacher Institute data. This dramatic shift enabled women to obtain abortions without visiting clinics, expanding access particularly in states with restrictive abortion laws. The mail-order system created new revenue streams for telehealth providers and pharmaceutical distributors operating under Biden-era regulatory frameworks.

Hawley’s legislation directly challenges this Biden administration legacy by targeting the drug itself rather than just distribution methods. The senator sent a letter to FDA Commissioner Marty Makary urging a comprehensive safety review, referencing Makary’s confirmation hearing pledge to examine all available data. The Ethics and Public Policy Center research cited by Hawley claims complication rates are 22 times higher than FDA-approved labeling indicates. However, the FDA has not provided a clear timeline or status update on any promised safety review, leaving the regulatory pathway uncertain while the legislative process unfolds.

Supreme Court Sidestepped Safety Questions

The Supreme Court unanimously rejected a 2024 challenge from the Alliance for Hippocratic Medicine seeking to reverse FDA approval of mifepristone. The ruling dismissed the case based on lack of legal standing rather than addressing the substantive safety claims about the drug’s risks. This procedural decision means the Court never evaluated the merits of arguments about mifepristone’s dangers, leaving those questions unresolved. Pro-life advocates view this as an opportunity for Congress to address safety concerns the judiciary declined to examine, while abortion access proponents argue the drug remains statistically safe for women to take.

The legislation faces significant obstacles despite Republican control of Congress. President Trump indicated as a candidate he would veto a national abortion ban, creating uncertainty about whether he would support Hawley’s bill or view it as federal overreach. Abortion restrictions have consistently failed to gain traction in Congress since the 2022 Dobbs decision returned regulation to individual states. The bill’s fate depends on whether Republican leadership prioritizes the measure and whether Trump administration officials, including FDA Commissioner Makary, provide data supporting the safety concerns Hawley has raised about this widely used pharmaceutical product.

Federal Ban Would Override State Protections

If enacted, Hawley’s legislation would eliminate the most common abortion method in America, fundamentally altering abortion access even in states with constitutional protections for reproductive rights. The federal prohibition would override state-level policies, creating tension in the post-Dobbs framework where abortion regulation returned to individual states. Women seeking medication abortion would lose access regardless of their state’s laws, forcing them toward surgical procedures or out-of-state travel. Telehealth providers, mail-order pharmacies, and reproductive health clinics currently distributing mifepristone would face federal prohibition, eliminating a significant service component and revenue stream.

The pharmaceutical industry would experience direct financial impact as mifepristone manufacturers face complete market elimination. The private right of action provision creates unprecedented liability exposure, allowing individual women to sue manufacturers for complications in a framework that could generate extensive litigation. This approach differs from typical pharmaceutical regulation where the FDA maintains primary oversight authority. Conservative supporters view the legislation as protecting women from corporate profits prioritized over safety, while critics characterize it as government overreach that substitutes congressional judgment for medical expertise and regulatory science.